Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:CALT NASDAQ:GOSS NASDAQ:MRUS NASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$34.11-3.3%$24.68$12.21▼$36.54$987.73M-0.18614,788 shs227,540 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AGOSSGossamer Bio$2.18-4.0%$2.57$0.66▼$3.60$516.15M1.943.49 million shs4.08 million shsMRUSMerus$94.60+0.2%$76.50$33.19▼$95.04$7.14B1.265.04 million shs1.52 million shsOGIOrganigram Global$1.72-5.5%$1.75$0.85▼$2.08$244.72M1.48884,676 shs787,226 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+1.88%+8.69%+69.29%+34.61%+0.86%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%GOSSGossamer Bio+3.65%-6.97%-25.57%+31.98%+135.97%MRUSMerus-0.47%-0.43%+38.43%+49.29%+79.24%OGIOrganigram Global0.00%-5.21%+1.11%+17.42%+2.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$34.11-3.3%$24.68$12.21▼$36.54$987.73M-0.18614,788 shs227,540 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AGOSSGossamer Bio$2.18-4.0%$2.57$0.66▼$3.60$516.15M1.943.49 million shs4.08 million shsMRUSMerus$94.60+0.2%$76.50$33.19▼$95.04$7.14B1.265.04 million shs1.52 million shsOGIOrganigram Global$1.72-5.5%$1.75$0.85▼$2.08$244.72M1.48884,676 shs787,226 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+1.88%+8.69%+69.29%+34.61%+0.86%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%GOSSGossamer Bio+3.65%-6.97%-25.57%+31.98%+135.97%MRUSMerus-0.47%-0.43%+38.43%+49.29%+79.24%OGIOrganigram Global0.00%-5.21%+1.11%+17.42%+2.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.67Moderate Buy$54.7860.59% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AGOSSGossamer Bio 2.67Moderate Buy$8.50289.91% UpsideMRUSMerus 2.16Hold$93.12-1.57% DownsideOGIOrganigram Global 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MRUS, ANAB, GOSS, OGI, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $70.0010/13/2025ANABAnaptysBioBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$78.0010/13/2025ANABAnaptysBioBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$78.0010/8/2025ANABAnaptysBioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GOSSGossamer BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MRUSMerusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OGIOrganigram GlobalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/6/2025MRUSMerusLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$95.00 ➝ $97.0010/5/2025MRUSMerusLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/30/2025MRUSMerusUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $97.009/30/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M10.46N/AN/A$2.33 per share14.64CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74GOSSGossamer Bio$114.70M4.32N/AN/A$0.13 per share16.77MRUSMerus$36.13M198.02N/AN/A$9.46 per share10.00OGIOrganigram Global$117.47M1.97N/AN/A$2.07 per share0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AGOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)OGIOrganigram Global-$33.39M$0.0534.41N/AN/A2.86%-8.19%-5.79%12/17/2025 (Estimated)Latest MRUS, ANAB, GOSS, OGI, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025GOSSGossamer Bio-$0.19N/AN/AN/A$6.32 millionN/A11/4/2025Q3 2025ANABAnaptysBio-$1.32N/AN/AN/A$15.83 millionN/A10/30/2025Q3 2025MRUSMerus-$1.20N/AN/AN/A$8.73 millionN/A8/13/2025Q3 2025OGIOrganigram Global-$0.01-$0.03-$0.02-$0.03$68.04 million$50.49 million8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 million8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22CALTCalliditas Therapeutics AB (publ)9.442.692.59GOSSGossamer BioN/A4.404.40MRUSMerusN/A8.398.39OGIOrganigram GlobalN/A2.591.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACALTCalliditas Therapeutics AB (publ)2.83%GOSSGossamer Bio81.23%MRUSMerus96.14%OGIOrganigram Global34.63%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%CALTCalliditas Therapeutics AB (publ)2.20%GOSSGossamer Bio6.70%MRUSMerus3.70%OGIOrganigram Global0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableGOSSGossamer Bio180227.38 million212.15 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableOGIOrganigram Global860134.46 million134.34 millionOptionableMRUS, ANAB, GOSS, OGI, and CALT HeadlinesRecent News About These CompaniesOrganigram Extends CEO’s Tenure Amid Ongoing SearchOctober 21 at 6:51 AM | tipranks.comOrganigram Global (NASDAQ:OGI) Trading 3.2% Higher - Should You Buy?October 16, 2025 | marketbeat.com3 Canadian Cannabis Stocks to Watch as U.S. Legalization Gains Steam in 2025October 16, 2025 | marijuanastocks.comMOrganigram Global (NASDAQ:OGI) Given "Sell (D)" Rating at Weiss RatingsOctober 10, 2025 | marketbeat.comOrganigram Launches ‘happly’ THC Gummies for Mindful RecreationOctober 9, 2025 | tipranks.comIs Organigram Global Inc. (TSE:OGI) Trading At A 50% Discount?September 30, 2025 | uk.finance.yahoo.comOrganiGram (OGI) Joins Cannabis Stock Rally After Trump Signals Policy ShiftSeptember 29, 2025 | benzinga.comOrganigram’s Report Highlights Cannabis as Key Economic Driver in CanadaSeptember 2, 2025 | tipranks.comOrganigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada’s GDP in 2024September 2, 2025 | financialpost.comFOrganigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada's GDP in 2024September 2, 2025 | businesswire.comOrganigram Global Inc. (OGI) Q3 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comOrganigram reports Q3 revenue $70.8M, consensus $68.04MAugust 13, 2025 | msn.comOrganigram Posts Wider Loss, Eyes Profitability In Near TermAugust 13, 2025 | benzinga.comOrganiGram (OGI) Reports Q3 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comOrganigram Reports Record Third Quarter Fiscal 2025 ResultsAugust 13, 2025 | financialpost.comFOrganigram Global Inc. (OGI) Expands Into U.S. THC Beverage Market Across 25 StatesAugust 2, 2025 | msn.comOrganigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025August 1, 2025 | financialpost.comFOrganigram Global Inc. (OGI) Stock Price Today - WSJJuly 15, 2025 | wsj.comShareholders in Organigram Global (TSE:OGI) are in the red if they invested five years agoJuly 9, 2025 | finance.yahoo.comOrganigram Expands U.S. Presence with Hemp-Derived THC Beverage LaunchJuly 8, 2025 | tipranks.comOrganigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage PortfolioJuly 8, 2025 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCirrus Logic's 52-Week High is More Than an Apple StoryBy Jeffrey Neal Johnson | September 26, 20253 Automation-Focused Stocks Flying Under the RadarBy Nathan Reiff | September 22, 2025Meta Debuts Next-Gen AI Glasses—A Turning Point for Reality Labs?By Leo Miller | September 28, 2025Lyft Surges on Waymo Robotaxi Deal: Is the Stock a Buy?By Leo Miller | September 22, 2025These 3 Stocks Just Got Upgraded—and Could Keep ClimbingBy Nathan Reiff | October 13, 2025MRUS, ANAB, GOSS, OGI, and CALT Company DescriptionsAnaptysBio NASDAQ:ANAB$34.11 -1.17 (-3.32%) Closing price 04:00 PM EasternExtended Trading$34.10 -0.01 (-0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 10/20/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Gossamer Bio NASDAQ:GOSS$2.18 -0.09 (-3.96%) Closing price 04:00 PM EasternExtended Trading$2.19 +0.01 (+0.46%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Merus NASDAQ:MRUS$94.60 +0.16 (+0.17%) Closing price 04:00 PM EasternExtended Trading$94.07 -0.53 (-0.56%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Organigram Global NASDAQ:OGI$1.72 -0.10 (-5.49%) Closing price 04:00 PM EasternExtended Trading$1.74 +0.03 (+1.45%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
